Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The aims of this study were to identify the value of inflammatory markers as pretreatment prognostic factors for patients with multiple myeloma (MM) and to estimate the value of a prognostic index including these markers at diagnosis. Methods: A total of 273 newly diagnosed MM patients undergoing active treatment were analyzed in this study. The prognostic values for survival of the pretreatment inflammatory markers were investigated. A myeloma prognostic index (MPI) was derived using prognostic factors determined to be independently significant on multivariate analysis. Results: A high pretreatment neutrophil-lymphocyte ratio (NLR), low platelet count, and high C-reactive protein (CRP) level had independently unfavorable significance for overall survival (OS). The MPI was derived based on these factors. Per the MPI, 1 point each was assigned to high NLR, low platelet count, and high CRP. Risk categories were stratified into low- (score 0), intermediate- (score 1), and high-risk (score 2 or 3) groups. The MPI demonstrated independent statistical significance for OS on multivariate analysis ([intermediate: hazard ratio (HR), 1.91; 95% confidence interval (CI), 1.12 to 3.24] and [high: HR, 3.37; 95% CI, 2.00 to 5.69]; p < 0.001). Moreover, this significance could be observed regardless of age, renal function, and exposure to novel agents. In addition, the International Staging System risk group could be further significantly stratified using the MPI. Conclusions: The MPI, consisting of pretreatment inflammatory markers, NLR, platelet count, and CRP, might be effective in predicting the survival of newly diagnosed MM patients undergoing active treatment.
Abstract
Background/Aims: The aims of this study were to identify the value of inflammatory markers as pretreatment prognostic factors for patients with multiple myeloma (MM) and to estimate the value of a prognostic index including these markers at diagnosis. Methods: A total of 273 newly diagnosed MM patients undergoing active treatment were analyzed in this study. The prognostic values for survival of the pretreatment inflammatory markers were investigated. A myeloma prognostic index (MPI) was derived using prognostic factors determined to be independently significant on multivariate analysis. Results: A high pretreatment neutrophil-lymphocyte ratio (NLR), low platelet count, and high C-reactive protein (CRP) level had independently unfavorable significance for overall survival (OS). The MPI was derived based on these factors. Per the MPI, 1 point each was assigned to high NLR, low platelet count, and high CRP. Risk categories were stratified into low- (score 0), intermediate- (score 1), and high-risk (score 2 or 3) groups. The MPI demonstrated independent statistical significance for OS on multivariate analysis ([intermediate: hazard ratio (HR), 1.91; 95% confidence interval (CI), 1.12 to 3.24] and [high: HR, 3.37; 95% CI, 2.00 to 5.69]; p < 0.001). Moreover, this significance could be observed regardless of age, renal function, and exposure to novel agents. In addition, the International Staging System risk group could be further significantly stratified using the MPI. Conclusions: The MPI, consisting of pretreatment inflammatory markers, NLR, platelet count, and CRP, might be effective in predicting the survival of newly diagnosed MM patients undergoing active treatment.
참고문헌 (25)
- Kyle RA, "Multiple myeloma", Blood, 111, pp.2962~2972 (2008)
- Siegel RL, "Cancer statistics, 2015", CA Cancer J Clin, 65, pp.5~29 (2015)
- Greipp PR, "International Staging System for multiple myeloma", J Clin Oncol, 23, pp.3412~3420 (2005)
- Balkwill F, "Inflammation and cancer: back to Virchow?", Lancet, 357, pp.539~545 (2001)
- Coussens LM, "Inflammation and cancer", Nature, 420, pp.860~867 (2002)
- Templeton AJ, "Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis", Cancer Epidemiol Biomarkers Prev, 23, pp.1204~1212 (2014)
- Zahorec R., "Ratio of neutrophil to lymphocyte counts:rapid and simple parameter of systemic inflammation and stress in critically ill", Bratisl Lek Listy, 102, pp.5~14 (2001)
- McMillan DC., "The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer", Cancer Treat Rev, 39, pp.534~540 (2013)
- Templeton AJ, "Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors:a systematic review and meta-analysis", J Natl Cancer Inst, 106, pp.dju124~ (2014)
- Keam B, "Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone", Leuk Lymphoma, 56, pp.2032~2038 (2015)
- Kelkitli E, "Predicting survival for multiple myeloma patients using baseline neutrophil", lymphocyte ratio, 2014, pp.93, 841~846
- Koh YW, "Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma", Am J Clin Pathol, 138, pp.846~854 (2012)
- Shrotriya S, "C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review", PLoS One, 10, pp.e0143080~ (2015)
- Bataille R, "C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system", Blood, 80, pp.733~737 (1992)
- Palumbo A, "Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group", J Clin Oncol, 33, pp.2863~2869 (2015)
- Chng WJ, "IMWG consensus on risk stratification in multiple myeloma", Leukemia, 28, pp.269~277 (2014)
- Hanahan D, "Hallmarks of cancer: the next generation", Cell, 144, pp.646~674 (2011)
- Barlogie B, "Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival", Ann Hematol, 90, pp.423~428 (2011)
- Black S, "C-reactive protein", J Biol Chem, 279, pp.48487~48490 (2004)
- Wang CS, "C-reactive protein and malignancy:clinico-pathological association and therapeutic implication", Chang Gung Med J, 32, pp.471~482 (2009)
- Kim SJ, "Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry", Acta Haematol, 122, pp.200~210 (2009)
- Jung SH, "Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen", Ann Hematol, 95, pp.55~61 (2016)
- Cook G, "Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes", J Leukoc Biol, 66, pp.981~988 (1999)
- Sakamaki S, "Transforming growth factor-beta1 (TGF-beta1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-beta receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-beta itself with high specificity", Blood, 94, pp.1961~1970 (1999)
- Fritz E, "Shortened platelet half-life in multiple myeloma", Blood, 68, pp.514~520 (1986)